Akcea therapeutics, inc. (AKCA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Revenue:
Revenue

16,074

277,480

20,624

26,623

163,816

10,197

19,241

18,321

17,108

21,688

9,906

5,713

6,094

-

-

Research and development revenue under collaborative agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Expenses:
Cost of sales - intangible asset amortization

1,419

1,434

1,434

1,419

1,403

2,012

701

-

-

-

-

-

-

-

-

Research and development

17,355

148,165

24,797

20,271

99,619

33,532

29,381

39,457

27,970

25,968

17,640

18,487

64,794

17,005

10,944

Selling, general and administrative

46,246

51,434

34,905

50,740

44,602

45,934

45,924

42,287

19,465

17,018

8,373

6,915

4,676

2,897

2,762

Total expenses

61,333

194,317

53,214

65,329

137,609

82,255

84,249

81,744

47,435

42,986

26,013

25,402

69,470

19,902

13,706

(Loss) income from operations

-45,259

83,163

-32,590

-38,706

26,207

-72,058

-65,008

-63,423

-30,327

-21,298

-16,107

-19,689

-63,376

-19,902

-13,706

Other income (expense):
Investment income

1,771

1,223

1,487

1,571

1,224

1,542

1,675

1,546

868

819

687

245

61

93

91

Interest expense

-

-

-

-

-

-

-

-

-

1

224

965

541

0

0

Other expense

-130

-339

-136

-28

-112

-41

-25

45

-168

-19

73

50

-

-

-

(Loss) income before income tax expense

-43,618

84,047

-31,239

-37,163

27,319

-70,557

-63,358

-61,832

-29,627

-20,498

-15,571

-20,359

-63,856

-19,809

-

Income tax benefit (expense)

-768

1,641

259

160

132

-

233

214

-

-791

2,066

-

-

0

-

Net (loss) income

-42,850

82,406

-31,498

-37,323

27,187

-70,557

-63,591

-62,046

-29,627

-19,707

-17,637

-20,359

-63,856

-19,809

-13,615

Net loss per share, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.47

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,884

Weighted-average shares of common stock outstanding, diluted

-

-

-

-

94,127

-

-

-

-

-

-

-

-

-

-

Product [Member]
Revenue

15,159

13,690

11,944

9,865

6,754

2,237

-

-

-

-

-

-

-

-

-

Cost of sales

3,364

1,197

967

1,364

1,041

777

1,043

-

-

-

-

-

-

-

-

Research and Development and License Revenue Under Collaborative Agreement [Member]
Revenue

915

259,790

8,544

10,722

157,062

7,960

7,241

18,321

17,108

21,688

9,906

5,713

6,094

-

-

Commercial Revenue [Member]
Revenue

-

-

-

-

-

2,237

-

-

-

-

-

-

-

-

-

Licensing [Member]
Revenue

-

4,000

136

6,036

-

-

12,000

-

-

-

-

-

-

-

-

Cost of product/license

-

2,400

-

3,000

-

-

7,200

-

-

-

-

-

-

-

-

Ionis [Member]
Net loss share from commercial activities under arrangement with Ionis Pharmaceuticals, Inc.

7,051

10,313

8,889

11,465

9,056

-

-

-

-

-

-

-

-

-

-

Preferred Stock [Member]
Net income (loss)

-

-

-

-

-

-

-

-

-

-

-64

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

1.12

-0.01

-0.70

-2.21

-

-

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-432

5,651

28,888

28,884

-

-

Common Stock [Member]
Net loss

-

-

-

-

-

-

-

0

-

-

-17,573

-

-

-

-

Weighted-average shares of common stock outstanding, basic

101,105

-

-

-

90,708

-

-

-

66,619

-

-

-

-

-

-